^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD8-H

    i
    Other names: CD8, CD8A, cluster of differentiation 8, CD8a Molecule, T-Cell Surface Glycoprotein CD8 Alpha Chain, T-Lymphocyte Differentiation Antigen T8/Leu-2, CD8 Antigen, Alpha Polypeptide (P32), Leu2 T-Lymphocyte Antigen, OKT8 T-Cell Antigen, T-Cell Antigen Leu2, T Cell Co-Receptor, T8 T-Cell Antigen, CD8a Antigen
    Entrez ID:
    925
    Related biomarkers:
    Expression
    Others
    11ms
    Prognostic assessment of T-cells in primary colorectal cancer and paired synchronous or metachronous liver metastasis. (PubMed, Int J Cancer)
    The second finding of high CD8+ cell density in pCRC in metachronous over synchronous CRC may provide a mechanistic basis for the delay of metastatic spread. Both findings could be applied clinically with own reference values.
    Retrospective data • Journal
    |
    CD8 (cluster of differentiation 8)
    |
    CD8-H
    11ms
    Significance of Tumor Microvasculature in the Tumor Microenvironment in Adenocarcinoma with EGFR Common Mutations. (PubMed, Ann Surg Oncol)
    In adenocarcinomas harboring EGFR common mutations, abundant tumor microvasculature might induce the TME to be immunosuppressive. Tumors with L858R mutation compared with Exon 19 Del might be more likely to form an immunosuppressive TME owing to the abundance of tumor microvasculature.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • CD8 (cluster of differentiation 8) • CD34 (CD34 molecule) • GZMB (Granzyme B) • FOXP3 (Forkhead Box P3)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • CD8-H
    11ms
    The expression of BHLHE22 in endometrial carcinoma: Associations with mismatch repair protein expression status, tumor-infiltrating immune cells, programmed death-ligand 1 and clinical outcomes. (PubMed, Taiwan J Obstet Gynecol)
    Increased numbers of CD8-positive cytotoxic T lymphocytes, CD68-positive macrophages, and PD-L1-positive tumor/immune cells were observed in MMR-deficient EC. BHLHE22 expression was associated with the PR regulatory and immune-related pathways.
    Clinical data • Journal • Mismatch repair • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PGR (Progesterone receptor) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • CD68 (CD68 Molecule)
    |
    PD-L1 expression • MSI-H/dMMR • PD-L1 overexpression • CD8 positive • CD8-H • CD68 positive
    11ms
    Distinct subtypes of post-transplant lymphoproliferative disorders: CHIP-like mutations in early lesions and substantial mutational differences between EBV-positive and EBV-negative diffuse large B-cell lymphomas. (PubMed, Br J Haematol)
    Gene expression profiling showed a significant overlap between 'early lesions' and polymorphic PTLD. The presence of clonal haematopoiesis of indeterminate potential (CHIP)-like mutations and the absence of immune-escape gene mutations in 'early lesions' suggest these disorders may represent clonal expansions driven by exogenic immunosuppression and/or EBV infection 'substituting' for mutations of the latter group of genes.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • NOTCH1 (Notch 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
    |
    TP53 mutation • NOTCH1 mutation • MYC rearrangement • CD8-H
    11ms
    Spatial proteomics reveals sirtuin 1 to be a determinant of T-cell infiltration in human melanoma. (PubMed, Br J Dermatol)
    Our study deciphers the proteomics landscape in human melanoma, providing important information on the tumour microenvironment and identifying SIRT1 as having important prognostic and therapeutic implications.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CD4 (CD4 Molecule) • SIRT1 (Sirtuin 1)
    |
    CD8 expression • CD8-H
    11ms
    Prognostic implications of immune classification based on PD-L1 expression and tumor-infiltrating lymphocytes in endocervical adenocarcinoma. (PubMed, Transl Oncol)
    TMIT I group within the NHPVA population is most likely to benefit from PD-L1/PD-1 blockade immunotherapies. The immune classification of ECA demonstrates significant prognostic value, suggesting its potential utility in guiding clinical stratification and therapeutic decision-making.
    Journal • Tumor-infiltrating lymphocyte • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
    |
    PD-L1 expression • CD8 expression • CD8-H
    11ms
    Activin A promoted the anti-tumor effect of ActRIIA high CD8+ T cells in mouse hepatoma. (PubMed, Cancer Med)
    This study demonstrated that low-dose activin A enhanced the anti-tumor effect of CD8+ T cells, and ActRIIA high CD8+ T cells actively contribute to tumor immunity.
    Preclinical • Journal
    |
    CD8 (cluster of differentiation 8) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD69 (CD69 Molecule) • ICOS (Inducible T Cell Costimulator) • GZMB (Granzyme B) • TGFB1 (Transforming Growth Factor Beta 1) • ITGAX (Integrin Subunit Alpha X) • KLRG1 (Killer Cell Lectin Like Receptor G1) • PRF1 (Perforin 1) • ACVR2A (Activin A Receptor Type 2A) • ITGA2 (Integrin Subunit Alpha 2) • METTL3 (Methyltransferase Like 3) • PPM1A (Protein Phosphatase Mg2+/Mn2+ Dependent 1A) • SMAD2 (SMAD Family Member 2)
    |
    CD8 expression • CD8-H
    12ms
    Characterization of tumor microenvironment and cell interaction patterns in testicular and diffuse large B-cell lymphomas. (PubMed, Haematologica)
    A high amount of CD163+ TAM interactions with distinct TILs translated to unfavorable survival both in GCB DLBCL and T-DLBCL, whereas a high number of interactions between TILs and TAMs, CD4+ TILs and TAMs, and CD4+ TILs and other TILs associated with favorable outcomes only in T-DLBCL. Together, our data demonstrate biologically and clinically relevant differences in the composition of and cellular interactions in the TME between various DLBCL entities.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • GZMB (Granzyme B)
    |
    CD8-H
    12ms
    PD-L1 Expression and Immune Infiltration Across Molecular Subtypes of Endometrial Cancer: An Integrative-Analysis of Molecular Classification and Immune Subtypes. (PubMed, Hum Pathol)
    Higher CD8+ T cell density was a prognostic marker for disease-free survival in EC, including within NSMP (p<0.05). In summary, the four WHO molecular subtypes of EC exhibit distinct TIME subtypes, complementing molecular classification and providing insights for optimizing EC immunotherapy strategies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • POLE (DNA Polymerase Epsilon) • CD8 (cluster of differentiation 8) • CD68 (CD68 Molecule)
    |
    PD-L1 expression • TP53 mutation • MSI-H/dMMR • POLE mutation • CD8-H
    |
    VENTANA PD-L1 (SP263) Assay
    1year
    A non-inferiority, phase III trial of gemcitabine plus capecitabine versus gemcitabine plus carboplatin as first-line therapy and tumor-infiltrating lymphocytes as a prognostic biomarker in patients with advanced triple-negative breast cancer. (PubMed, Ther Adv Med Oncol)
    However, the GX regimen should be considered in patients who cannot tolerate hematological toxicity. ClinicalTrials.gov identifier: NCT02207335.
    P3 data • Journal • Head-to-Head • Tumor-infiltrating lymphocyte • Metastases
    |
    CD8 (cluster of differentiation 8)
    |
    CD8-H
    |
    carboplatin • gemcitabine • capecitabine
    1year
    Higher Expression of Ku80 and Ku70 Indicates Hotter Tumor Immune Microenvironment in Hepatocellular Carcinoma and Better CTL-Centered Immunotherapy. (PubMed, J Inflamm Res)
    Higher Ku70/Ku80 expression indicated an immune-hot infiltration signature in HCC. Patients with increased Ku70/Ku80 expression and high CD8+CTL signatures may potentially benefit from CTL-centered immunotherapies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    CD8 expression • CD8-H
    1year
    Spatial distributions of CD8 and Ki67 cells in the tumor microenvironment independently predict breast cancer-specific survival in patients with ER+HER2- and triple-negative breast carcinoma. (PubMed, PLoS One)
    Computational biomarkers, representing spatial properties of the tumor proliferation and immune cell infiltrates, provided independent prognostic information beyond conventional IHC markers in BC. Integrating Ki67-entropy and CD8-immunogradient indicators into prognostic models can improve patient stratification with regard to BCSS.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8)
    |
    HER-2 positive • ER positive • HER-2 negative • CD8 positive • CD8-H • HER-2 negative + ER positive